Free tool
FAERS Monitor: Minipress
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017442 or its brand name (Minipress, Prazosin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,387
Serious
873
63% of reports
Hospitalization
415
Death reported
91
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue115
- off label use106
- abdominal pain105
- product dose omission issue104
- drug ineffective91
- nausea89
- diarrhoea75
- pain74
- renal impairment72
- heart failure with preserved ejection fraction69
- headache67
- dyspnoea63
- hypotension62
- dizziness60
- haematuria60
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 9 |
| 2006 | 6 |
| 2008 | 4 |
| 2009 | 15 |
| 2010 | 22 |
| 2011 | 12 |
| 2012 | 21 |
| 2013 | 18 |
| 2014 | 12 |
| 2015 | 14 |
| 2016 | 16 |
| 2017 | 22 |
| 2018 | 17 |
| 2019 | 32 |
| 2020 | 47 |
| 2021 | 65 |
| 2022 | 177 |
| 2023 | 144 |
| 2024 | 244 |
| 2025 | 298 |
| 2026 | 183 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,772 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| heart failure with preserved ejection fractionSignal | 69 | 4654.8 | 3572.8 | 242,150 |
| haematuriaSignal | 60 | 26.6 | 20.8 | 1,453 |
| renal impairmentSignal | 72 | 13.0 | 10.4 | 789 |
| abdominal painSignal | 105 | 6.8 | 5.7 | 524 |
| product dose omission issueSignal | 104 | 5.4 | 4.5 | 370 |
| hypotensionSignal | 62 | 4.7 | 3.7 | 178 |
| fatigueSignal | 115 | 2.2 | 1.9 | 81 |
| off label use | 106 | 1.8 | 1.5 | 41 |
| pain | 74 | 1.8 | 1.5 | 28 |
| dizziness | 60 | 1.8 | 1.4 | 22 |
| diarrhoea | 75 | 1.8 | 1.4 | 25 |
| nausea | 89 | 1.7 | 1.4 | 26 |
| dyspnoea | 63 | 1.7 | 1.3 | 17 |
| headache | 67 | 1.6 | 1.3 | 16 |
| drug ineffective | 91 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.